Hexo (TSE:HEXO) had its price objective increased by Canaccord Genuity from C$7.50 to C$10.00 in a research note issued to investors on Friday morning.
Several other research firms have also weighed in on HEXO. CIBC increased their price objective on shares of Hexo from C$8.50 to C$9.50 in a research note on Friday. BMO Capital Markets increased their price objective on shares of Hexo from C$6.00 to C$9.00 in a research note on Friday. Jefferies Financial Group reiterated an underperform rating and set a C$5.60 price objective on shares of Hexo in a research note on Monday, February 25th. Finally, Oppenheimer assumed coverage on shares of Hexo in a research note on Tuesday, February 19th. They set an outperform rating and a C$7.00 price objective on the stock.
Shares of Hexo stock traded down C$0.01 during trading on Friday, reaching C$8.10. The company had a trading volume of 9,188,900 shares, compared to its average volume of 3,608,023. The firm has a market cap of $1.68 billion and a PE ratio of -38.21. Hexo has a fifty-two week low of C$3.34 and a fifty-two week high of C$9.29.
Hexo Company Profile
HEXO Corp., through its subsidiary, HEXO Operations Inc, produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names.
Recommended Story: How do candlesticks reflect price movement?
Receive News & Ratings for Hexo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hexo and related companies with MarketBeat.com's FREE daily email newsletter.